Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2009

Health Discovery Enters Deals with Abbott and Quest Diagnostics for Prostate Cancer Tests

  • Health Discovery (HDC) inked two separate agreements related to its prostate cancer diagnostic program. It has given Abbott the right to commercialize its gene-based tests for clinically significant prostate cancer.

    Abbott acquired coexclusive clinical laboratory rights and exclusive in vitro diagnostic rights for HDC’s tissue-based and urine-based prostate cancer test.

    Additionally, HDC licensed rights to Quest Diagnostics for the development of a urine-based test for clinically significant prostate cancer. Under the terms of this agreement, HDC will receive payments, royalties, and additional undisclosed financial considerations.

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »